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1  Introduction 
The use of opioid analgesics is still the most effective way to manage moderate to 
severe pain in the clinic. Nevertheless, the use of opioid analgesics is associated with 
the significant risk of respiratory depression. A meta-analysis of 165 papers with data 
for  nearly  20,000  patients  found  an  incidence  of  ventilatory  depression  related  to 
opioid administration after surgery of up to 17% [1]. Importantly, fatal outcomes after 
opioid administration are still observed even under controlled conditions in the clinical 
setting and in young patients without major pathology [2]. Selective antagonism of the 
respiratory  depressive  effects  of  opioids  without  decreasing  their  analgesic  effects 
would be a major step toward opioid safety.  
In rats, the ampakine CX717 has been shown to counteract opioid-induced ventilatory 
depression. When given alone, it did not stimulate ventilation [3-4]. Since CX717 does 
not interact with the µ-opioid receptor, it does not act as a direct antagonist opposing 
analgesic  opioid  effects.  Moreover,  while  nociceptive  neurons  do  express  AMPA 
receptors,  administration  of  ampakines  did  not  affect  nociceptive  behaviour  in 
laboratory animals [4]. The availability of CX717 for use in humans has now opened the 
possibility to examine the utility of CX717 as a selective antidote for the prevention of 
opioid induced ventilatory depression.  
The  present  study  was  aimed  at  establishing  a  proof-of-concept  of  whether  the 
selective  antagonism  of  opioid  induced  ventilatory  depression  by  an  ampakine 
translates to humans. We conducted a placebo-controlled, double-blinded cross-over 
design to assess the effects of pre-administered CX717 on opioid induced ventilatory 
depression and analgesia in healthy human volunteers. 
1.1  Opioid analgesics and respiration depression 
1.1.1  Molecular target of the majority of opioid analgesics: µ-opioid receptors 
On the molecular level, morphine and other clinically used opioid analgesics act via 
activation  of  a  group  of  G-protein  coupled  receptors,  the  opioid  receptors.  Four Introduction 
6 
different opioid receptor subtypes are known, the μ- (mu), δ- (delta) and κ- (kappa) 
receptors, and the opioid receptor-like protein (ORL1) [5-6]. Only recently it has been 
shown  that  µ-opioid  receptor  activation  is  primarily  responsible  for  the  wanted 
analgesic  but  also  the  unwanted  side-effects,  e.g.,  respiratory  depression,  of  the 
majority of opioid analgesics. Mu-opioid receptor-knockout mice did not respond to 
morphine with analgesia, respiratory depression, constipation, physical dependence 
reward  behaviors,  or  immunosuppression  [7].  In  contrast,  no  behavioral  responses 
related to δ- or κ-opioid receptor activation were observed although these receptors 
were still present in these mice.  
Mu-opioid  receptors  are  extensively  expressed  in  pain  processing  pathways  of  the 
whole central nervous system (CNS) including the dorsal horn of the spinal cord, brain 
stem and sub-cortical and cortical brain regions. Thus, the effects of opioid analgesics 
can be found on nearly every level of pain transmission and perception [8-9]. The 
activation  of  µ-opioid  receptors  by  opioid  analgesics  leads  to  the  decrease  of  the 
release of excitatory neurotransmitters from pre-synaptic neurons into the synaptic 
cleft  and  to  hyperpolarisation  of  post-synaptic  neurons,  resulting  in  a  reduced 
excitability of nociceptive pathways and brain regions involved in pain perception. 
Activation of µ-opioid receptors triggers also numerous unwanted side effects such as 
e.g., respiratory depression, nausea, miosis and constipation. Some of them can be 
attributed to the activation of peripheral opioid-receptors (e.g., constipation, urinary 
retention) [8], but mostly the unwanted side effects can be tracked to opioid sensitive 
nuclei in the brain stem [10].  
1.1.2  Respiration 
Respiration is a complex physiological act that is influenced by several mechanisms 
including chemoreceptors, airway protective reflexes and neurotransmitters. The pre-
Bötzinger complex, a small area in the ventrolateral medulla, plays an important role in 
generating  respiratory  rhythm  together  with  the  retrotrapezoid  nucleus/  parafacial 
respiratory group (pFRG) [11-12]. In vitro experiments showed that the pre-Bötzinger 
complex was able to maintain an inspiratory rhythm, while the pFRG showed a more Introduction 
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pronounced  effect  on  expiratory  activity.  Both  centers  contribute  to  rhythm 
generation  in  vivo,  but  as  breathing  in  resting  conditions  consists  mainly  in  active 
inspiration followed by passive expiration, the rhythm is generated mainly by the pre-
Bötzinger  complex.  A  high  percentage  of  the  pre-Bötzinger  neurons  were 
propriobulbar neurons, i.e., had axonal arborization in the medulla, connecting them 
to further bulbospinal neurons located e.g., in the ventrolateral reticular formation 
which served as pre-motoneurons transmitting to spinal respiratory motoneurons. It 
has  been  shown  that  these  oscillatory  active  neurons  bared  the  characteristics  of 
conditional  pacemaker  neurons,  as  they  responded  to  depolarization  with  voltage 
depending bursts of oscillations. Microinjection of K
+ produced a temporary increase in 
motor burst frequency while a reduction of the local synaptic transmission with an 
NMDA-Antagonist  reduced  the  frequency  and  eliminated  the  oscillatory  output. 
Isolated lesions in the pre-Bötzinger complex would be first apparent during sleep 
followed  by  perturbations  during  awareness  [12],  as  the  influence  of  the  pFRG 
increases with increasing activity. Animal studies were able to demonstrate, that only 
the bilateral destruction of the pre-Bötzinger complex lead to ataxic breathing pattern 
and  pathological  responses  to  hypoxia  [13]  indicating  its  ability  to  compensate  a 
unilateral  loss.  Respiratory  rhythm  is  furthermore  a  result  of  the  coupled  network 
between pre-inspiratory-neurons (pre-I-neurons) and pre-Bötzinger-complex-neurons 
[14].  
 
1.1.3  Effects of µ-opioid receptor activation on respiration: respiratory depression 
In contrast to pre-I-neurons, neurons responsible for rhythm generation in the pre-
Bötzinger  complex  have  been  shown  to  be  opiate-sensitive.  Slice  preparations 
including only the opioid sensitive pre-Bötzinger complex neurons bathed in the µ-
opioid  agonist  DAMGO  showed  gradually  slowing  of  respiratory  periods  which 
returned  to  normal  after  application  of  naloxone.  However,  bath  application  of 
DAMGO to en bloc preparations of the brainstem, including also pre-I-neurons initially 
showed a gradual slowing of respiratory periods that abruptly changed to a quantal-
slowing pattern, which results from transmission failure of inspiratory bursts to opioid-Introduction 
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depressed pre-Bötzinger-neurons, while the central respiratory rhythm, maintained by 
pre-I-neurons was not altered [14-15]. 
1.2  Re-establishing  normal  respiration  during  opioid  treatment 
without affecting analgesia 
1.2.1  The challenge 
The  incidence  of  opioid-induced  respiratory  depression  in  a  relatively  secure 
environment such as the postoperative setting in the recovery room remains up to 
17% [1, 16]. Even under such controlled clinical conditions opioid administration can 
result  in  fatal  respiratory  depression  [17-21],  requiring  a  tight  medical  supervision 
including  measurements  of  blood  oxygenation  level  and  thus  needing  experienced 
staff and medical equipment. In critical conditions the respiratory depression must be 
reversed  by  administration  of  the  specific  antagonist  naloxone,  making  pain 
management in these situations very difficult, as naloxone not only antagonizes the 
unwanted side effects, but also the wanted analgesia. The fear of putting patients at a 
risk  of  respiratory  depression  may  also  lead  to  an  under  dosing  of  opioids  and 
therefore inadequate analgesia. Control of the respiratory effects of opioids without 
decreasing its analgesia would imply a significant improve for pain therapy as most 
fatal outcomes under opioid influence can be explained by the unwanted effects on 
respiration. 
1.2.2  Possible targets to selectively prevent opioid induced respiratory depression 
Several  attempts  have  already  been  made  to  counteract  respiratory  depression 
without influencing opioid-induced analgesia. Some of those attempts targeted the 
Serotonin receptor system, based on the theory, that morphine induces respiratory 
depression  involving  the  serotoninergic  neurons  in  the  brainstem,  through  a 
serotoninergic raphe nucleus discharge resulting in a blockade of synaptic inhibition 
within  the  pre-Bötzinger  complex,  leading  to  a  sustained  excitation  of  respiratory 
neurons  and  a  disturbed  respiratory  activity.  5HT1A-agonists  presumably  act  as 
autoreceptors  and  inhibit  the  serotoninergic  discharge.  Another  promising  way  to Introduction 
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prevent  selectively  opioid-induced  respiratory  depression,  was  targeting  5HT7  or 
5HT4a-receptors, as an activation here leads to a G-protein mediated increase in cAMP, 
and as both receptors could be positively identified in neurons of the pre-Bötzinger 
complex, also expressing µ-opioid receptors (exerting their effect through a G-protein 
mediated decrease in cAMP), agonists at those receptors were postulated to directly 
counteract µ-opioid mediated respiratory depression. 
1.2.3  Translational attempts to prevent opioid induced respiratory depression 
8-OH-DPAT and buspirone, both 5HT1A-agonists, were able to restore breathing in rats 
with opioid-induced respiratory depression [22-23]. An attempt to translate this model 
from  animal  research  to  humans  failed,  possibly  due  to  an  insufficient  effect  site 
concentration achievable in humans [24]. Agonists at 5HT7 and 5HT4a–receptors were 
also examined in this context [25-27]. BIMU8, a 5HT4a-receptor agonist reestablished 
respiratory activity within minutes in rats treated previously with fentanyl, without a 
measurable  antagonistic  effect  on  analgesia.  Mosapride,  the  only  5HT4a-receptor 
agonist available for the use in humans, failed to counteract respiratory depression in a 
similar way [28], possibly explained by a lower potency and a worse brain penetration 
compared to BIMU8. 
1.2.4  Activation  of  AMPA-receptors:  A  new  way  to  control  opioid  induced 
respiratory depression without affecting analgesia 
In  vitro  experiments  showed  that  local  perturbation  of  excitatory  aminoacid 
neurotransmission  provoked  an  increase  in  respiratory  burst  frequency  and  tonic 
discharge of inspiratory output [29]. Application of neuromodulators, including 5-HT, 
GABA and µ-opioids affected the respiratory frequency by acting on neurons within 
the  pre-Bötzinger  complex.  The  synaptic  interactions  between  propriobulbar 
respiratory neurons in the pre-Bötzinger complex involve excitatory amino acids acting 
on  non-NMDA-glutamate  receptors,  more  specifically  on  the  subgroup  of  AMPA 
receptors [11]. Blocking this receptor by injection of 6-cyano-7-nitroquinoxaline-2,3-
dione (CNQX), a non-NMDA-receptor-antagonist, completely depletes the respiratory 
rhythm. Also the phosphorylation of postsynaptic AMPA receptors through cAMP-PKA, Introduction 
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an  endogenously  active  kinase,  modulate  respiratory  currents  in  pre-Bötzinger-
inspiratory neurons [30]. Activation of PKA with forskolin increases the frequency of 
motor  output,  while  PKA  inhibition  decreases  respiratory  frequency.  The  local 
application  of  α-amino-3-hydroxy-5-methylisoxazole-4-propionate  (AMPA)  produced 
inward currents in the hypoglossus nerve, which serves as a site of measurement for 
respiratory  output  and  proofs  that  AMPA  receptors  are  essential  for  respiratory 
rhythm  generation  [31].  Strengthening  this  theory,  bath  application  of  the  non-
competitive  AMPA  receptor  antagonist  1-(4-aminophenyl)-4-methyl-7,8-
methylenedioxy-5H-2,3-benzodiazepine  (GYKI)  completely  abolished  hypoglossus 
motoneuron  output  and  blocked  respiratory  related  drives  in  the  pre-Bötzinger 
complex, while the local application of GYKI to the pre-Bötzinger complex completely 
blocked respiratory rhythm generation [32]. Contrariwise local application of AMPA 
increased respiratory burst frequency and depolarized respiratory neurons.  
The above mentioned results indicate that the AMPA receptor with its agonists and 
antagonists plays an important role in rhythm generation, including phosphorylation of 
the receptor site as a factor modulating respiratory motor output. This implies perhaps 
a new working point for influencing respiratory depression induced by opioids. 
Development of molecules specifically acting on AMPA receptors opens the possibility 
to counteract the respiratory depressive effects of opioids, without interfering with the 
desired  analgesia.  The  experimental  compound  CX717,  1-(benzofurazan-5-
ylcarbonyl)morpholine,  used  in  this  study  acts  by  allosterically  binding  to  AMPA 
receptors  as  agonist,  increasing  AMPA  receptor  gated  currents  at  the  presence  of 
glutamate, and thus influencing respiratory rhythm generation [4]. Anatomical and in 
vitro  studies  suggest  that  while  µ-opioid  sensitive  neurons  in  the  pre-Bötzinger 
complex  are  responsible  for  opioid  induced  respiratory  depression  [33],  rhythm 
generation  and  inspiratory  drive  transmission  can  also  be  influenced  by  the 
experimental  compound  CX717  through  involved  AMPA  receptors.  This  would 
hopefully counteract the µ-agonistic effect of opioids on respiration. Differing from 
other AMPA agonists, which act on the cyclothiazide binding site, the ampakine CX717 
binds  on  another  still  unidentified  binding  site  and  is  categorized  as  “low  impact” 
compound. This novel group of AMPA receptor agonist does not seem to show up-Introduction 
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regulation of trophic factors, such as the brain-derived-neurotrophic-factor (BDNF). As 
AMPA-receptors are mainly expressed in the central nervous system, a specific agonist 
is not expected to have a measurable effect at peripheral sites, reducing the likelihood 
for  serious  side  effects,  and  respiratory  depression  could  be  influenced  without 
interfering with the desired opioid induced analgesia. 
In  vivo  and  in  vitro  experiments  showed  that  the  application  of  CX546,  an  earlier 
developed  compound,  stimulated  baseline  respiratory  frequency  and  was  able  to 
reverse  opioid-induced  respiratory  depression;  encouraging  the  development  of 
further compounds. An animal study with the compound used in this study, CX717, 
also has already been successful [4]. Respiratory depression in rats induced by the µ-
opioid  agonist  fentanyl responded to  CX717,  decreasing the  respiratory  depression 
without interfering with analgesia. 
1.3  Aim of the study 
Aim  of  this  study  was  to  proof,  whether  the  selective  antagonism  of  CX717  on 
respiratory depression could be translated to humans. We therefore used a placebo-
controlled;  double-blinded  cross-over  design  to  assess  the  effects  of  CX717 
preadministration  on  alfentanil  induced  ventilatory  depression  and  analgesia  in 
otherwise healthy human volunteers. 
 Material and Methods 
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2  Material and Methods 
The study protocol complied with the Declaration of Helsinki on Biomedical Research 
Involving  Human  Subjects  (Somerset  West  amendment)  and  was  approved  by  the 
Ethics Committee of the Medical Faculty of the Goethe-University Frankfurt am Main, 
Germany. 
2.1  Study population 
A total of 28 male candidates were screened for the study. Carriers of the µ-opioid 
receptor mutation N40D were excluded because this might have been a confounder of 
respiratory depressive opioid effects [34]. Furthermore, subjects in whom capsaicin 
application  during  the  training  session  did  not  produce  a  decrease  in  heat  pain 
tolerance by at least 10% (“capsaicin non-responders”) were excluded. Two candidates 
withdrew  their  written  informed  consent  prior  to  the  beginning  of  the  study.  Ten 
candidates  failed  to  meet  the  inclusion  or  exclusion  criteria,  respectively  (physical 
examination: 2; laboratory tests: 2; N40D carriers: 4; capsaicin non-responders: 2) 
We enrolled 16 healthy young men (age 26.6 ±4.6 years, body mass index 23.4 ± 2.7 
kg/m²; mean ± standard deviation). It was deemed adequate to restrict subjects to 
males  since  the  inclusion  of  women  was  not  expected  to  provide  any  further 
information regarding proof of concept, although there is no indication that CX717 is 
associated with reproductive toxicity in animal tests [35]. Subjects were recruited via 
flyers distributed at the campus of the University of Frankfurt am Main. Calculation of 
sample size was based on previously obtained data [36]. It resulted in 11 subjects 
needed to establish an antagonism of ventilatory depression by 50 %. 
2.2  Study design 
This  trial  was  designed  as  a  randomized,  double-blind,  placebo-  and  naloxone-
controlled, two-way cross-over study. Setup was chosen to assess the effects of the 
experimental compound CX717, compared to placebo, on opioid-induced respiratory 
depression. Naloxone served as a positive control and was not blinded. The aim of this Material and Methods 
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study was to assess, whether CX717 would have an antagonizing effect on opioid-
induced respiratory depression without affecting the opioid-intended analgesia.  
Each of the subjects were randomized in one of two equal proportioned groups and 
completed two study periods receiving CX717 and Placebo in the sequence AB or BA, 
maintaining a washout period of 7 days in between.  
In addition, if a volunteer showed to be eligible for this study a training session was 
performed to familiarize the subject with the experimental assessments planned to 
perform  during  the  study  periods.  Thereafter  each  subject  had  to  complete  two 
identically designed study periods. After completing the second study period subjects 
had to attend to a follow-up session in order to assess adverse events or permanent 
damages.  
Each study period comprised a baseline session which meant to assess test responses 
prior  to  administering  the  medication.  Subjects  were  required  to  fast  before  each 
study period. Alcohol was prohibited the 24h prior a study day and any medication was 
prohibited  for  30  days  preceding  the  experiments.  A  single  oral  dose  of  CX717  or 
placebo was then administered with 240 ml of lukewarm water. Peak concentrations 
of CX717 were anticipated at approximately 120 min after administration. Thus at both 
study occasions at 100 min after CX717 administration a computerized intravenous 
alfentanil infusion was started targeting constant plasma concentrations of 100 ng/ml 
during the following further assessments for a total of 120 min. During both study 
periods subjects received alfentanil in an open label fashion and completed a second 
testing session assessing the effects alfentanil produced on breathing and analgesia 
starting at 120 min after CX717 administration. By allowing 20 min for equilibration, 
the  effect  site  concentrations  of  alfentanil  can  be  considered  as  equal  to  plasma 
concentrations. To evaluate respiratory depression we used two different methods. 
First, the individual answer to a CO2-Rebreathing challenge was recorded followed by 
an additional recording of 6 minutes of spontaneous respiration. Two models were 
chosen in order to assess whether CX717 had an effect on respiratory rhythm as well 
as its effect on hypercapnic stimuli. Analgesia was assessed by means of two different 
peripheral pain models. We chose to assess pain tolerance to transcutaneous electrical Material and Methods 
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stimulation  and  to  heat  pain.  Both  pain  models  were  equally  established  in  this 
institute and expected to be able to capture opioid effects as well as the influence of 
CX717. After assessing both respiratory and analgetic effects for the second time, each 
subject received a short infusion of naloxone, started at 160 min after administration 
of CX717 or placebo, intended to antagonize completely the opioid related effects. 
Immediately  following  the  administration  of  naloxone,  a  third  assessment  session 
consistent with the previous assessment sessions completed each study period. 
The temporal succession of the measurements relative to the administration of the 
medications is shown below.  
 
Figure 1: Assessment schedule of the CX717 and the placebo condition. Each study condition consisted of three similar sessions, at baseline (Session 1), after initiation of the 
alfentanil infusion (Session 2) and after the end of the naloxone injection (Session 3). During each session the assessments of ventilatory depression, pain side effects and vital 
signs was performed. In addition at baseline heat pain values were recorded prior to performing the capsaicin sensitization. Blood sample times and medications are indicated 
below the assessments, and the anticipated alfentanil plasma (and brain) concentrations are also depicted with a dotted line. 
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2.3  Study medication 
2.3.1  CX717 
A single oral dose of 1500 mg of CX717 or placebo was administered after baseline 
assessment on each study period. Subjects were told to swallow five identically looking 
tablets together with 240ml of lukewarm tab water provided by the investigator. Study 
medication  was  manufactured  by  the  St.  Hubertus  pharmacy,  Berlin,  Germany, 
following  randomization  codes  provided  from  an  external  study  site.  Placebo  and 
tablets containing the experimental compound were identically looking maintaining 
the double-blind design of the study. Intake was always observed by the investigator.  
2.3.2  Alfentanil 
In this clinical trial, the participants received in an open-label fashion an intravenous 
infusion  of  alfentanil  hydrochloride  (Rapifen®,  JANSSEN-CILAG  GmbH,  Neuss, 
Germany). Alfentanil was chosen because of its fast equilibration between plasma and 
effect site, the central nervous system (CNS), which allows to consider the plasma 
concentrations as being similar to the brain concentrations after 5 min equilibration 
time  (t½(ke0)(Alfentanil)  =  0.6-1.2  minutes  [37]).  In  addition,  the  fast  equilibration 
between  plasma  and  brain  and  the  short  duration  of  alfentanil  action  allowed  for 
keeping  the  duration  of  the  experiments  short  and  ensured  quick  recovery  of  the 
subjects from the opioid effects after the end of the alfentanil infusion. To maintain a 
constant  alfentanil  concentration  at  the  effect site,  alfentanil  was  administered  by 
means of computerized infusion using STANPUMP program ([38] freely available from 
Steven  L.  Shafer,  MD  at  http://anesthesia.stanford.edu/pkpd)  with  Scott’s 
pharmacokinetic  parameters  for  alfentanil  (weight  adjusted;  [37])  and  the  Harvard 
pump  22  (Instech  Laboratories,  Plymouth  Meeting,  PA,  USA)  targeting  a  constant 
plasma concentration of 100 ng/ml. The alfentanil target concentration of 100 ng/ml 
has  been  chosen  to  ensure  measurable  ventilatory  depression  and  analgesia  [34] 
without jeopardizing the subjects’ health.  Material and Methods 
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2.3.3  Naloxone 
Immediately after the second assessment session, at 160 min after administration of 
the experimental compound CX717, subjects received a total dose of 1.6 mg naloxone 
(DeltaSelect GmbH, Dreieich, Germany) administered by a constant rate intravenous 
infusion for 20 min without interrupting the alfentanil infusion. Naloxone was chosen 
due to its characteristic unselective antagonism of all opioid-related effects. 
2.4  Assessment of pharmacodynamic parameters 
2.4.1  Respiratory depression  
2.4.1.1  Provoking hyperventilation by means of CO2 re-breathing  
Respiratory  depression  was  assessed  by  means  of  CO2  re-breathing.  The  CO2  re-
breathing was executed according to Read´s method [39] with slight modifications. The 
subjects were instructed to re-breathe into a plastic bag connected to a special device 
(Oxycon  Pro,  Jaeger,  Hoechberg,  Germany)  that  continuously  recorded  the  minute 
expiratory volume (VEmin), end-tidal CO2 levels (pCO2) and ventilatory rate. Being a 
closed system, the re-breathing leads to an increase of the CO2 concentration in the 
plastic bag and as a consequence in the lungs and the body fluids. The progressive rise 
of the CO2 concentration in the body fluids due to the continuing metabolism results in 
an activation of chemoreceptors in the respiratory center. Thus, breathing is further 
stimulated, finally resulting in hyperventilation, which is indicated by an increase of the 
minute expiratory volume. To prevent the development of any hypoxic stimulus to the 
ventilation  [39],  the  plastic  bag  was  filled  with  oxygen  (O2)  prior  starting  the 
experiment. The high initial O2 concentration in the re-breathing bag provided enough 
O2 for metabolism, assuring the subjects well-being throughout the assessment. The 
slope of the linear relationship between the VE [min] and pCO2 (
x
y
D
D , see Figure 2) is 
defined  as  the  primary  target  parameter  for  the  quantification  of  the  respiratory 
depressive effect. In addition, another reliable parameter is the expiratory volume per 
minute at a CO2 concentration of 55 mmHg (VE55), which can be calculated from the 
slope and intercept of the obtained linear relationship between expiratory volume and Material and Methods 
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CO2 concentration [40]. While changes in the x- and y- intercepts can be misleading 
and therefore should not be used as parameter, a decrease in the slope and VE55 can 
be  considered  as  a  reliable  indication  for  respiratory  depression  during  opioid 
treatment. This method has repeatedly demonstrated to reliably assess the respiratory 
depressive effects of morphine and alfentanil [28, 41]. 
 
Figure  2:  Respiratory  depression.  Assessment  of  the  respiratory  depression  by  means  of  CO2  re-
breathing. Fictitious data acquired during a typical CO2-rebreathing test. The minute expiratory volume 
(VE) rises with increasing CO2 concentration (dots). Data is analyzed by fitting a linear equation to the 
data. Respiratory depression is indicated by a decrease  of the slope of the linear relationship or a 
decrease of the minute expiratory volume at a CO2 concentration of 55 mmHg (VE55). 
∆x
p(CO ) 2
∆y
55
mmHg
y=A+b•x
(-A/b)
VE
VE(55 mmHg)
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2.4.1.2  Monitoring of spontaneous respiration 
Additionally,  opioid  induced  respiratory  depression  was  measured  by  analyzing 
changes in the frequency of spontaneous breathing (Figure 3). Therefore, a respiratory 
belt transducer (MLT1132 Piezo Respiratory Belt transducer, ADInstruments GmbH, 
Spechbach,  Germany)  was  fastened  around  the  subject’s  upper  abdomen  and 
connected to an integrated data recording unit featuring a built-in amplifier (Powerlab 
4/25T, ADInstruments GmbH, Spechbach, Germany). The subjects were instructed to 
remain  silent,  while  recording  their  respiratory  frequency  for  a  period  of  10  min, 
during which slow music was played and the laboratory was otherwise kept completely 
silent. The first three and the last minute were rejected from analysis, in order to allow Material and Methods 
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the subject to adept to testing atmosphere and to normalize breathing. Respiratory 
depression is indicated by a decrease in the respiratory frequency (Breaths/minute). 
 
Figure 3 Monitoring of spontaneous respiration: Fictitious data acquired during the experiment. Each 
peak represents a single breath. Results were presented as number of breaths per minutes 
 
. 
2.4.2  Assessment of analgesia 
2.4.2.1  Heat pain tolerance threshold 
Heat stimuli were applied with a 3 x 3 cm thermode placed on the skin of the left volar 
forearm using a Thermal Sensory Analyzer (Medoc advanced Medical Systems Ltd., 
Ramat  Yishai,  Israel).  Stimuli  Temperature  was  continuously  increased  by  0.8°C/s 
starting at 32°C with a maximum temperature of 52.5°C. Pressing a button by the 
subject triggered  cooling  of  the  thermode by  10°C/s  down to  32.5°C subsequently 
starting  the  next  stimulus  sequence  after  an  interstimulus  interval  of  20-25  s.  To 
increase  model  sensitivity  and  avoid  reaching  the  technical  maximum  of  52.5°C, 
primary  hyperalgesia  [42]  was  induced  by  applying  capsaicin  cream  (0.2%, 
manufactured by the local pharmacy of the University Hospital Frankfurt am Main) 
onto the skin area and occluding it with a plaster. 
To quantify the individual heat pain tolerance, defined as the change of sensation from 
painful heat to intolerable heat, heat stimuli started with a temperature of 32.5°C Material and Methods 
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close to skin temperature and thus known not to be painful. Analgesia was assessed 
using increasing heat stimuli. Subjects were previously instructed to press a button 
when the pain reached intolerability in order to stop warming the thermode (Figure 4). 
After reaching again default temperature of 32.5°C the next stimulus sequence started 
as described above. A total of 8 heat stimuli were applied in this manner. As previous 
experiments  showed  that  tolerance  temperature  reached  a  plateau  after  the  first 
three measurements, the median of the last five responses was used as heat pain 
tolerance. 
The analgesic effect of alfentanil is expected to appear as an increase in heat pain 
tolerance.  As  the  heat  stimulus  device  gave  a  limit  of  52.5°C  in  order  to  prevent 
permanent damaging of the skin, we tried to lower the individual heat pain tolerance 
with capsaicin. This allowed us to retrieve quantifiable heat pain tolerance values even 
under the opioid induced analgesia. First heat pain assessment was performed at the 
very beginning of the study period, followed by application of capsaicin cream (0.2%, 
manufactured by the local pharmacy) onto the same area the thermode had been 
placed previously. This area was immediately covered with a plaster for at least 30 
min, while performing the other baseline experiments. After removing the plaster, the 
measurements  of  heat  pain  tolerance  were  repeated  exactly  in  the  same  way  as 
described above. Capsaicin application to the tested area is expected to lower heat 
pain  tolerance  by  a  minimum  of  10%.  If  any  of  the  subjects  would  not  show  this 
reaction during training session, he would be excluded from further participation in 
the study and declared as capsaicin non-responder. 
In order to prolong the capsaicin effect for as long as study assessments lasted, the 
tested area was covered with a transparent plaster immediately after each heat pain 
assessment.  After  completion  of  the  last  testing  session  capsaicin  residuals  were 
removed,  and  the  area  was  cooled  if  requested  by  the  subject.Material and Methods 
21 
 
Figure  4:  Heat  pain  model:  The  subjects  received  heat  pain  stimuli  of  continuously  increasing 
temperature (rate 0.8°C) starting at a temperature of 32.5°C with a maximum of 52.5°C. Temperature 
increased until the subject stopped heating by pressing a button. Subsequently, cooling of the heating 
device was triggered until it reached again baseline temperature. The next stimulus was started after an 
interstimulus interval of 20-25s. The pain threshold was obtained as the median from the last 5 of a 
total of 8 stimuli applied 
 
2.4.2.2  Transcutaneous electrical stimulation 
Short electrical stimuli (2 s) of increasing intensity were applied to the subjects´ left 
forefinger (Figure 5). A constant current device (NEUROMETER CPT, Neurotron Inc., 
Baltimore, MD, USA) with a maximum output of 20 mA was used to administer painful 
electrical  5Hz  sine  wave  pulses  via  two  gold  electrodes  placed  on  the  medial  and 
lateral side of the distal phalangeal joint (middle finger of the left hand as default-
testing site). The electrical stimulus has been shown to primarily activate C-fibers [43-
44] and thus to be able to capture µ-opioid receptor mediated analgesia. 
To assess each individuals pain tolerance threshold after electrical stimulation, i.e., the 
electrical  current,  when  the  subjects  pain  experience  changes  from  tolerable  to 
intolerable, the stimulation started with an electrical current known not to be painful, 
while  starting-stimulus  intensity  ranged  randomly  between  0.2  mA  and  2  mA.  The 
current was then further increased in an ascending staircase design until the subjects 
reported to feel pain (Figure 5). The magnitude of subsequent stimuli was determined 
by the subject’s response to the two preceding stimuli. If a subject’s response to two 
preceding stimuli was “no pain – no pain” or “pain – pain” the next stimulus was equal Material and Methods 
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to the magnitude of the last delivered stimulus plus or minus 130% of the difference 
between the last and the second last stimulus, respectively. If a subject’s response to 
two preceding stimuli was “no pain – pain” or “pain – no pain” the next stimulus was 
equal to the magnitude of the second last stimulus plus 75 or 25% of the difference 
between  the  last  and  the  second  last  stimulus,  respectively.  The  purpose  of  the 
outlined algorithm was to increase or decrease the magnitude of delivered stimuli 
quickly  as  long  as  a  subject  gave  a  uniform  response,  i.e.,  “no  pain”  or  “pain”. 
Whenever a subject changed the response from “no pain” to “pain” or from “pain” to 
“no pain”, the outlined algorithm allowed the magnitude of stimuli evoking a change in 
response at a higher resolution. Subsequently, the pain threshold was obtained from 
10 stimuli by logistic regression of “pain” or “no pain” (corresponding to “0” or “1”) 
versus  the  intensity  of  the  electrical  current.  The  interstimulus  interval  was 
approximately 30-60 s. After opioid administration an increase of the pain tolerance 
threshold is expected, as this pain model has been repeatedly demonstrated to be 
suitable  to  quantify  the  analgesic  effects  of  opioids  such  as  hydromorphone  [44], 
morphine [45], remifentanil [46], or alfentanil [34]. Material and Methods 
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Figure 5: Electrical pain model: The subjects received a 5 Hz sine waves pulses with a length of two 
seconds in the range from 0-20 mA with an interstimulus interval of approximately 30-60 s. The amount 
of the electrical current was increased until the subject described the stimulus as painful. Subsequently, 
the current is decreased until the subject describes the stimulus as non painful. Whenever a subject 
changes the response from “no pain” to “pain” or from “pain” to “no pain”, the outlined algorithm 
allows the magnitude of stimuli evoking a change in response at a higher resolution. Subsequently, the 
pain threshold was obtained from a maximum of 10 stimuli by logistic regression of “pain” or “no pain” 
(corresponding to “0” or “1”) versus the intensity of the electrical current. 
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2.5  Assessment of opioid related medical symptoms 
Medical  symptoms  reported  by  the  subjects  and  the  occurrence  of  vomiting  were 
recorded by the investigator. Opioid related side-effects such as tiredness, nausea, 
drowsiness and itching were rated by the subject using visual analogue-scales (VAS, 
length 100mm ranging from 0=”no such symptom” to 100=”symptom experienced at 
maximum”)  at  the  beginning  of  each  testing  session,  i.e.,  at  baseline,  after 
equilibration time of alfentanil and after infusion of naloxone. 
 Material and Methods 
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2.6  Analysis of drug plasma concentrations 
To  assure  that  all  subjects  received  similar  treatment,  drug  plasma  concentrations 
were determined by means of liquid chromatographic tandem mass spectrometric (LC-
MS/MS). Therefore, venous blood samples (4 ml) were collected into Na-EDTA tubes at 
predefined  time  points  (n=6  samples  for  alfentanil  and  CX717  per  study  day,  n=3 
samples for naloxone), with an additional sample taken before administrating any of 
the medication, serving as blank value. After centrifugation at 3000 rpm for 10 min, 
plasma was separated, kept on ice until the end of the study day and then frozen at -
78°C pending further analysis.  
2.6.1  CX717 
Aliquots of plasma samples obtained during testing sessions were sent to the US and 
analyzed at Enthalpy Analytical Inc, Durham, USA. Further information regarding the 
analyzing process was not available. 
2.6.2  Alfentanil 
Aliquots  of  plasma  samples  were  further  analyzed  to  assure  similar  effect  site 
concentration in all subjects. Alfentanil (Janssen-Cilag, Neuss, Germany) was extracted 
by  protein  precipitation  using  fentanyl  (Janssen-Cilag,  Neuss,  Germany)  as  internal 
standard. Therefore, 20 µl human plasma were thoroughly mixed with 20 µl fentanyl-
solution (12 ng/ml in acetonitrile), 50 µl acetonitrile and 200 µl methanol. Calibration 
standards  were  prepared  in  the  same  manner  with  blank  human  plasma 
(Blutspendedienst  Hessen,  Frankfurt  am  Main,  Germany),  but  instead  of  50  µl 
acetonitrile, 50 µl of standard solution in acetonitrile was used. The samples were 
centrifuged for 5 min at 10,000 g and 20 µl of the supernatant was diluted with 200 µl 
acetonitrile/formic acid (100:0.25, v/v). After another 5 min of centrifugation at 10,000 
g,  100  µl  of  the  solution  was  transferred  to  glass  vials  (Macherey-Nagel,  Düren, 
Germany)  prior  to  injection  into  the  LC-MS/MS  system.  The  LC-MS/MS  system 
consisted of an API 4000 triple-mass spectrometer (Applied Biosystems, Darmstadt, 
Germany) equipped with a Turbo-V-source operating in positive ESI mode, an Agilent 
1100 binary HPLC pump and degasser (Agilent, Böblingen, Germany) and a HTC Pal Material and Methods 
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autosampler (Chromtech, Idstein). For the chromatographic separation an Alltima HP 
HILIC column and precolumn were used (50 x 2.1 mm I.D., 3 µm particle size from 
Alltech,  Unterhaching,  Germany).  Mobile  phase  was  acetonitrile/water/formic  acid 
(90:10:0.25, v/v/v), flow rate was 700 µl/min and total run time 2.5 min. Injection 
volume of samples was 20 µl. Retention time of alfentanil and fentanyl was 1.16 min 
and  1.03  min,  respectively.  HPLC-solvents  were  of  HPLC-quality  (Merck  KgaA, 
Darmstadt,  Germany).  Multiple  reaction  monitoring  (MRM)  was  used  for 
quantification. The mass transitions used were m/z 417 ® m/z 268 for alfentanil and 
m/z 337 ® m/z 188 for fentanyl. Quantitation was performed with Analyst Software 
V1.4 (Applied Biosystems, Darmstadt, Germany) using the internal standard method 
(isotope-dilution mass spectrometry): Ratios of alfentanil and fentanyl peak area were 
plotted against concentration. Lower limit of quantification of alfentanil was 0.1 ng/ml 
(14 fg on column). Accuracy of the method over the calibration range (0.1 to 500 
ng/ml) was 100.01 ± 5.98 % (n = 8). 
2.6.3  Naloxone  
Similarly aliquots of human plasma samples were extracted by solid phase extraction 
and the eluate was analyzed for naloxone. Briefly, 100 µl internal standard containing 
30  ng/ml  naltrexone  and  800  µl  water  were  added  to  100  µl  plasma.  Solid  phase 
extraction was performed on a system consisting of Oasis HLB extraction cartridges (1 
ml volume, 30 mg sorbent, Waters, Eschborn, Germany) attached to a Visiprep vacuum 
manifold (Supelco, Deisenhofen, Germany). The extraction column was activated with 
1 ml methanol and 1 ml water. After the sample was drawn through, the column was 
washed with 1 ml water and dried under a vacuum of -20 mm Hg (-68 kPa) for 7 min. 
The substances were eluted from the column with 1 ml methanol. The organic solvent 
was evaporated to dryness by a gentle stream of nitrogen at 40°C. The residue was 
reconstituted with 100 µl of the mobile phase. Calibration standards were prepared in 
drug free human plasma and assayed at the beginning of each sequence. For control of 
inter-assay variation, spiked quality control samples in plasma were measured in each 
run among samples. Material and Methods 
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The HPLC equipment consisted of an Agilent 1100 Series binary pump (G1312A) and 
degasser  (G1379A)  connected  to  a  HTC  PAL  autosampler  (Chromtech,  Idstein, 
Germany).  Chromatographic  separations  were  obtained  under  gradient  conditions 
using a Synergi Hydro-RP column (150 mm L × 2 mm I.D., 4 µm particle size and 80 Å 
pore  size)  (Phenomenex,  Aschaffenburg,  Germany).  The  mobile  phase  consisted  of 
eluent A (water with 5 mM ammonium acetate) and eluent B (methanol with 5 mM 
ammonium acetate). The gradient was as follows: From t = 0 to t = 0.5 min A/B 99:1, 
followed from t = 0.5 to t = 7.5 min by a linear gradient from 99:1 to 10:90, then from t 
= 7.5 to t = 10.5 min 10:90, from t = 10.5 to t = 11 min a linear gradient from 10:90 to 
99:1 and finally from t = 11 to t = 14.5 min A/B 99:1. 10 µl of the extracted sample 
were  injected  onto  the  LC-MS/MS.  The  flow  rate  was  set  at  0.3  ml/min  and  the 
runtime at 14.5 min. Naloxone and the internal standard naltrexone eluted after 10.5 
and 10.3 min, respectively. 
MS and MS/MS analyses were performed on a 4000 Q TRAP triple quadrupole mass 
spectrometer with a Turbo V source (Applied Biosystems, Darmstadt, Germany). For 
measurement of naloxone and naltrexone the positive ion mode was chosen. High 
purity nitrogen was used as nebulizer, curtain, auxiliary/turbo heater and collision gas. 
The heated turbo gas was set at 550 °C. Quantitation was performed in the multiple 
reaction mode (MRM) using nitrogen as the collision gas with a collision energy of 55 
and  39  V  for  naloxone  and  naltrexone,  respectively.  Precursor-to-product  ion 
transitions of m/z 328®212 for naloxone and m/z 342®270 for naltrexone were used 
for the MRM with a dwell time of 50 ms. 
Concentrations  of  the  calibration  standards,  quality  controls  and  unknowns  were 
evaluated by Analyst software (version 1.4; Applied Biosystems, Darmstadt, Germany). 
Linearity  of  the  calibration  curve  was  proven  from  0.6  to  120 ng/ml. Variations  in 
accuracy  and  intra-day  and  inter-day  precision  (n  =  6  for  each  concentration, 
respectively) were < 15% over the range of calibration. Material and Methods 
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2.7  Statistics 
Data was submitted to multivariate analysis of variance for repeated measures (rm-
ANOVA), with “session” (i.e., baseline, session 2: alfentanil + placebo/CX717, session 3: 
alfentanil + placebo/CX717 + naloxone; degrees of freedom, df = 2) and “CX717” (i.e., 
CX717  or  placebo;  df  =  1)  as  within-subject  factors.  Pharmacokinetic  data  were 
analyzed analogously except fewer degrees of freedom of "session" for alfentanil or 
naloxone that had not been present at baseline and/or session 2, respectively. Post-
hoc comparisons were done by t-tests with α-correction (Bonferroni). Effect sizes of 
CX717 were computed as Cohen's d, which quantifies the standardized difference in 
parameter  means  between  the  effect  of  interest,  percent  changes  at  session  2  as 
compared to baseline during the CX717 condition, and the placebo effect, percent 
changes at session 2 as compared to baseline during the placebo condition, calculated 
as 
Combined SD
Mean Mean
d
2 1 -
= . The accepted interpretation is a value of d = 0.2 as indicative of a 
small effect, 0.5 of a medium and 0.8 of a large effect size [47]. Statistics were done 
with PASW 17.0.2 for Windows (SPSS Inc., Chicago, IL, USA). The α-level was set at 
0.05. Results 
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3  Results 
All  16  subjects  completed  the  study  as  planned  and  side  effects  were  mild  to 
moderate. No medical intervention was necessary. Side effects were typical for opioid 
analgesics and included tiredness, drowsiness, nausea, vomiting and itching. 
3.1  Plasma concentrations 
The  pharmacodynamic  results  were  obtained  at  similar  alfentanil  plasma 
concentrations during the placebo and CX717 conditions (106.0 ± 8.5 ng/ml and 97.4 ± 
11.6 ng/ml, respectively; rm-ANOVA factor “session”: F (1,13) = 0.10; rm-ANOVA factor 
“CX717”: F (1,13) = 4.4, p = 0.06; interaction “session” by “CX717”: F (1,13) = 0.01, p = 
0.94; see Figure 6 and Table 1). The naloxone plasma concentrations during session 3 
did also not differ between placebo and CX717 conditions (36.1 ± 11.1 and 35.1 ± 
15.3 ng/ml, respectively; t-test: p = 0.78). CX717 plasma concentrations followed a 
plateau during the measurements after baseline and were equal during session 2 and 3 
(15.4 ± 0.7 mg/ml; rm-ANOVA factor “session”: F (1,15) = 0.007, p = 0.94).  Results 
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Figure  6:  Plasma  concentrations  of  alfentanil,  CX717  and  naloxone  during  time-course  of  the  study 
period 
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Table 1: Plasma concentrations of alfentanil, CX717, and naloxone during Session 2 and Session 3 
    Session 2 (alfentanil)  Session 3 (alfentanil + 
naloxone) 
Plasma concentrations  N  + Placebo  + CX717  + Placebo  + CX717 
Alfentanil 
1 [ng/ml] 
14  103.3 ± 27.3  94.8 ± 31.7  108.8 ± 37.4  99.9 ± 56.2 
CX717 
2 [mg/ml] 
16  -  15.4 ± 2.9  -  15.4 ± 2.9 
Naloxone 
3 [ng/ml]  16  -  -  36.1 ± 11.1  35.1 ± 15.3 
1 rm-ANOVA: Main effect “CX717”, F(1,13) = 4.4, p = 0.06; main effect “session”, F(1,13) = 0.98, p = 0.34; 
interaction “CX717” x “session”, F(1,13) = 0.01, p=0.94 
2 rm-ANOVA: Main effect “session” F(1,15) = 0.01, p = 0.94 
3 t-test: t(15) = 0.28, p = 0.78 
3.2  Ventilatory effects 
During placebo co-administration, alfentanil decreased the respiratory frequency from 
13.1 ± 3.1 min
-1 at baseline by 25.6 ± 27.9% to 9.2 ± 2.8 min-1 at session 2 (Figure 7 A 
and Table 2) which was reversed by naloxone (session 3: 12.2 ± 2.5 min
-1). During the 
CX717 condition, alfentanil decreased the respiratory frequency only from 12.2 ± 3.1 
min
-1  at  baseline  by  2.9  ±  33.4%  to  11.1  ±  2.7  min
-1  at  session  2.  After  naloxone 
administration, the respiratory frequency returned to 12.4 ± 3 min
-1 (session 3). The 
significance of the CX717 effect was revealed by an interaction "session" by "CX717": F 
(2,28) = 6.8, p = 0.004. In addition, the respiratory frequency differed between sessions 
(F (2,28) = 5.8, p = 0.008) whereas "CX717" had no significant main effect (F (1,14) = 
0.3, p = 0.27) which fits with the similar baseline and post-naloxone measurements 
during  placebo  and  CX717  conditions.  Post-hoc  t-tests  specified  that  session  2 
(alfentanil) differed significantly from baseline during the placebo (p < 0.01) but not 
the CX717 condition (p > 0.2). 
The blood oxygen saturation paralleled the observations with respiratory frequency. 
That is, alfentanil decreased the oxygen saturation from 97.6 ± 0.9% spO2 at baseline 
to 94.9 ± 0.9% at session 2, which was reversed by naloxone to 97.2 ± 0.9% (Figure 7 B 
and Table 2). During CX717 co-administration, the changes were smaller (baseline: Results 
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97.6 ± 0.9% spO2, session 2: 96.2 ± 1.5%, session 3: 97.6 ± 1.1%). The significance of 
the CX717 effect was again seen as an interaction "session" by "CX717": F (2,26) = 7, p 
= 0.004, and the blood oxygenation differed significantly between sessions (F (2,26) = 
33.3, p < 0.001) whereas "CX717" had no significant main effect (F (1,13) = 3.7, p = 
0.08).  This  fits  with  the  similar  baseline  and  post-naloxone  measurements  during 
placebo  and  CX717  conditions.  Post-hoc  t-tests  specified  that  session 2  (alfentanil) 
differed significantly from baseline during the placebo (p < 0.05) but not the CX717 
condition (p > 0.2). Results 
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Figure  7:  Ventilatory  Effects.  Opioid  effects  on  spontaneous  respiration  were  attenuated  by  the 
ampakine CX717. The respiratory frequency (A) and the blood oxygen saturation (B) decreased with 
increasing alfentanil concentrations (n = 15 and n = 14, respectively). This was reversed by the naloxone 
injection. During CX717 co-administration, the opioid induced decrease of the respiratory frequency and 
blood oxygen saturation was significantly less than under placebo co-administration 
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Table 2: Descriptives and statistics of the key parameters of ventilatory depression and analgesia during baseline, session 2 and session 3 (N = number of subjects 
included in the analysis). 
    Descriptives      Statistics     
   
Baseline  
(pre-dose) 
Session 2  
(alfentanil) 
Session 3  
(alfentanil + naloxone) 
Main effect 
“CX717” 
Main effect 
"Session" 
Interaction 
"CX717"x"Session" 
Parameter  N  + Placebo  + CX717  + Placebo  + CX717  + Placebo  + CX717 
F-value 
p-value 
F-value 
p-value 
F-value 
p-value 
Respiratory 
frequency [min
-1] 
15  13.1 ± 3.1  12.2 ± 3.3  9.2 ± 2.8  11.1 ± 2.7  12.2 ± 2.5  12.4 ± 3.0 
F(1,14) = 0.3 
p = 0.27 
F (2,28) = 5.8 
p = 0.008 
1 
F (2,28) = 6.8 
p = 0.004 
Hem. 
oxygenation [% 
spO2] 
14  97.6 ± 0.9  97.7 ± 0.9  94.9 ± 1.8  96.2 ± 1.5  97.2 ± 0.9  97.6 ± 1.1 
F (1,13) = 
3.7 
p = 0.08 
F (2,26) = 33.3  
p < 0.001 
2 
F (2,26) = 7.0 
p = 0.004 
Slope 
[l · min
-1 · mmHg
-
1] 
15  1.35 ± 0.68  1.43 ± 0.68  0.49 ± 0.31  0.68 ± 0.29  1.21 ± 0.48  1.11 ± 0.44 
F (1,14) = 
1.7 
p = 0.22 
F (2,28) = 32.5  
p < 0.001 
3 
F (2,28) = 3.8 
p = 0.035 
VE at 55 mmHg 
CO2 [l · min
-1] 
15  37.9 ± 16.3  40.5 ± 16.5  16.7 ± 6.3  21.9 ± 7.3  35.8 ± 12.4  35.6 ± 10.0 
F (1,14) = 
6.4 
p = 0.024 
F (2,28) = 31.5  
p < 0.001 
F (2,28) = 2.8 
p = 0.08 
Electrical pain 
tolerance [mA] 
16  4.1 ± 1.1  4.6 ± 1.6  7.0 ± 2.4  7.2 ± 2.6  4.4 ± 1.3  4.0 ± 1.3 
F (1,15) = 
0.1 
p = 0.75 
F (2,30) = 38.6 
p < 0.001 
4 
F (2,30) = 2.4 
p = 0.11 
Heat pain 
tolerance [°C] 
16  38.6 ± 4.0  38.1 ± 3.2  48.1 ± 3.9  46.9 ± 3.2  45.4 ± 3.3  44.6 ± 3.5 
F (1,15) = 2 
p = 0.18 
F (2,30) = 154.3 
p < 0.001 
5 
F (2,30) = 0.3 
p = 0.73 
1 Post-hoc t-test: Session 2 differed significantly from baseline during the placebo (p < 0.001) but not during the CX717 condition (p > 0.2) 
2 Post-hoc t-test: Session 2 differed significantly from baseline during the placebo (p < 0.05) but not during the CX717 condition (p > 0.2) 
3 Post-hoc t-test: Session 2 differed significantly from baseline during the placebo (p < 0.01) and during the CX717 condition (p < 0.01) 
4 Post-hoc t-test: Session 2 differed significantly from baseline during both, the placebo and the CX717 condition (p < 0.001) 
5 Post-hoc t-test: Session 2 differed significantly from baseline during both, the placebo and the CX717 condition (p < 0.001)Results 
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With hypercapnic challenge during placebo co-administration, alfentanil decreased the 
slope of the linear relationship between minute expiratory volume and the carbon 
dioxide concentration in expired air from 1.35 ± 0.68 l min
-1 ·mmHg
-1 at baseline to 
0.49  ±  0.31  l  min
-1  ·mmHg
-1  at  session  2  (Figure  8  and  Table  2).  It  returned  after 
naloxone administration to 1.21 ± 0.48 l min
-1 ·mmHg
-1. During the CX717 condition, 
alfentanil decreased this slope less (baseline: 1.43 ± 0.68 l·min
-1 ·mmHg
-1, session 2: 
0.68 ± 0.29 l·min
-1 ·mmHg
-1, session 3: 1.11 ± 0.44 l·min
-1 ·mmHg
-1). The significance of 
the CX717 effect was revealed by an interaction "session" by "CX717": F (2,28) = 3.8, p 
= 0.035. In addition, the slope differed between sessions (F (2,28) = 32.5, p < 0.001) 
whereas "CX717" had no significant main effect (F (1,14) = 1.7, p = 0.22). However, the 
reversal by CX717 was incomplete as reflected in significant post-hoc t-tests: session 2 
(alfentanil) versus baseline (p < 0.01) during both placebo and CX717 conditions (p < 
0.01). The calculated value of VE55 showed a similar tendency as the slope (Figure 8 
and Table 2). During placebo co-administration, alfentanil decreased VE55 from 37.9 ± 
16.3 l min
-1 at baseline by 53.7 ± 16.6% to 16.7 ± 6.3 l min
-1 at session 2. It returned 
after naloxone administration to 35.8 ± 12.4 l min
-1. The opioid-associated decrease 
was smaller (by 40.9 ± 24.3%) during CX717 co-administration (baseline: 40.5 ± 16.5 l 
min
-1, session 2: 21.9 ± 7.3 l·min
-1, session 3: 35.6 ± 10 l·min
-1). The baseline difference 
was  reflected  in  a  significant  main  effect  of  "CX717"  (F  (1,14)  =  6.4,  p  =  0.024). 
"session" had also a significant main effect on VE55 (F (2,28) = 31.5, p < 0.001) whereas 
the  interaction  "CX717"  by  "session"  displayed  only  a  tendency  toward  statistical 
significance in this parameter (F (2,28) = 2.8, p = 0.08). Results 
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Figure 8: Ventilatory effects. CX717 significantly attenuated the opioid induced hypercapnic response. 
Representative data  from one subject of the relationship  between  expiratory volume (VE) and CO2 
concentration in the inspired air (A) before and (B) after administration of alfentanil, and  (C) after 
administration of naloxone (median/solid line, mean/dotted line, 5
th and 95
th percentiles/bars). Opioid 
effects on all measured respiratory parameters were attenuated by the ampakine CX717. Similarly, (D) 
the  slope  of  the  linear  relationship  between  expiratory  volume  (VE)  and  CO2  concentration  in  the 
inspired air and (E) the calculated expiratory volume per minute at 55 mmHg p CO2 (VE55) decreased 
after alfentanil administration (n = 15). Both parameters were also restored by naloxone injection. Results 
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3.3  Analgesic effects 
CX717  did  not  affect  opioid  induced  analgesia.  During  placebo  co-administration 
alfentanil  increased  the  pain  tolerance  to  electrical  stimuli  from  4.1  ±  1.1  mA  at 
baseline by 76.4 ± 71.4% to 7 ± 2.4 mA at session 2, which was reversed by naloxone to 
4.4 ± 1.3 mA (session 3; Figure 9 A and Table 2). During CX717 co-administration, 
alfentanil increased the electrical pain tolerance from 4.6 ± 1.1 mA at baseline by 57.6 
± 26.0% to 7.2 ± 2.6 mA at session 2, which was reversed by naloxone to 4 ± 1.3 mA 
(session 3). The effect of CX717 was not significant as shown by the absent interaction 
"session" by "CX717": F (2,30) = 2.4, p = 0.11. In addition, the pain tolerance differed 
between "sessions" (F (2,30) = 38.6, p < 0.001) but not "CX717" (F (1,15) = 0.1, p = 
0.75). Post-hoc t-tests specified that session 2 (alfentanil) differed significantly from 
baseline during both the placebo and CX717 conditions (p < 0.001). 
CX717 co-administration did also not affect the alfentanil-induced increase in heat pain 
tolerance.  Specifically,  during  the  placebo  condition  pain  tolerance  increased  from 
38.6 ± 4 °C at baseline to 48 ± 3.9°C at session 2 (Figure 9 B and Table 2). It was 
reduced  under  the  influence  of  naloxone  to  45.4  ±  3.3  °C.  Similarly,  during  the 
ampakine condition pain tolerance increased from 38.1 ± 3.2 °C at baseline to 46.9 ± 
3.2 °C at session 2 and was reduced after naloxone to 44.6 ± 3.5 °C. Again, the effect of 
CX717 was not significant (interaction "session" by "CX717": F (2,30) = 0.3, p = 0.73) 
whereas pain tolerance differed between "sessions" (F (2,30) = 154.3, p < 0.001) but 
not "CX717" versus placebo (F (1,15) = 2, p = 0.18). Post-hoc t-tests specified that 
session 2 (alfentanil) differed significantly from baseline during both the placebo and 
CX717 conditions (p < 0.001).  
The effect sizes of CX717 versus placebo were larger for respiratory depression than 
for analgesia related parameters. The effects on respiratory depression were medium 
for respiratory rate (d = -0.694) and VE55 (d = -0.65), and large for the slope of the 
linear relationship between expiratory volume and the CO2 concentration in expired air Results 
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in the re-breathing experiment (d = -0.8). In contrast, the effects on analgesia were 
small (electric pain tolerance: d = -0.35, heat pain tolerance: d = -0.2). 
Figure  9:  Analgesic  effects:  (A)  Electrical  pain  tolerance  and  (B)  heat  pain  tolerance  of  capsaicin 
sensitized  skin  increased  after  alfentanil  administration  (n  =  16).  The  electrical  pain  tolerance  was 
reversed to baseline levels after naloxone administration. The alfentanil induced increase of heat pain 
tolerance was significantly but incompletely antagonized by naloxone and did not reach baseline levels. 
CX717 had no statistically significant influence on the analgesic effects. 
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3.4  Side effects 
CX717 was tolerated by all subjects without the occurrence of side effects requiring 
medical  intervention.  Under  placebo  co-administration,  the  alfentanil  infusion 
significantly  increased  tiredness,  drowsiness,  nausea  and  itching,  which  was 
significantly  reduced  by  naloxone  with  the  exception  of  nausea  that  increased 
immediately after naloxone injection. While CX717 co-administration did not affect 
drowsiness, nausea and pruritus, it led to a significantly more pronounced increase in 
tiredness during alfentanil administration (placebo condition: baseline: 19.8 ± 22.8 mm 
VAS, session 2 (alfentanil): 33.2 ± 28 mm, session 3 (alfentanil + naloxone): 15.3 ± 10.1 
mm; CX717 condition: baseline: 8.9 ± 9.7 mm, session 2 (alfentanil): 36.2 ± 30.4 mm, 
session 3 (alfentanil + naloxone): 13.9 ± 11.6 mm; rm-ANOVA interaction “session” by 
“CX717”:  F  (2,30)  =  3.9,  p  =  0.03;  see  Table  3).  Tiredness  also  differed  between 
“session” (F (2,30) = 6.2, p = 0.006) whereas "CX717" alone had no significant main 
effect (F (1,15) = 1.6, p = 0.23) Results 
 
Table 3: Descriptives and statistics of the side effects tiredness, drowsiness, nausea and pruritus during baseline, session 2 and session 3 (N = number of subjects included in 
the analysis) 
    Descriptives      Statistics     
    Baseline (pre-dose)  Session 2 (alfentanil) 
Session 3 (alfentanil + 
naloxone) 
Main effect 
“CX717” 
Main effect 
"Session" 
Interaction 
"CX717"x"Session" 
Parameter  N  +Placebo  +CX717  +Placebo  +CX717  +Placebo  + CX717  F-value 
p-value 
F-value 
p-value 
F-value 
p-value 
Tiredness  
[mm VAS] 
16  19.8  
± 22.8 
8.9 ± 9.7  33.2 ± 28  36.2  
± 30.4 
15.3  
± 10.1 
13.9  
± 11.6 
F(1,15)=1.6 
 p = 0.23 
F(2,30)=6.2 
p = 0.006  
F(2,30)=3.9 
 p=0.03 
Drowsiness  
[mm VAS] 
16  5 ± 13.6  1.2 ± 2.3  46.9 ± 23  43.7  
± 23.2 
13.9  
± 17.1 
15.2  
± 11.4 
F(1,15)=0.4 
 p = 0.52 
F(2,30)=44.4 
p = 0.000  
F(2,30)=0.41 
 p=0.67 
Nausea  
[mm VAS] 
16  0.3  
± 0.6 
0.3 ± 0.5  1.6 ± 3.1  9.4  
± 18.3 
10  
± 10.8 
15.4  
± 18.1 
F(1,15)=4.1 
 p = 0.06 
F(2,30)=8.4 
p = 0.001  
F(2,30)=1.8 
 p=0.19 
Pruritus  
[mm VAS] 
16  1.4  
± 3.7 
0.3 ± 0.4  20.9 ± 22.2  15.4  
± 21.1 
0.4  
± 1.3 
0.7  
± 1.7 
F(1,15)=1.1 
 p = 0.31 
F(2,30)=16 
p = 0.00  
F(2,30)=0.6 
 p=0.54 
 Discussion 
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4  Discussion 
The  results  of  this  study  successfully  proofed  the  concept,  that  opioid  induced 
ventilatory depression can be selectively antagonized in humans by co-administering 
an ampakine. While naloxone antagonized both opioid induced ventilatory depression 
and analgesia, CX717 selectively antagonized ventilatory depression.  
This  is  the  first  successful  translation  of  a  selective  antagonism  of  opioid-induced 
ventilatory  depression  from  animals  [4]  to  humans.  It  follows  several  unsuccessful 
attempts to translate similarly aimed but molecularly alternative mechanisms from 
animal research [22, 27] to humans [48-49]. Previously explored mechanisms targeting 
the  serotonin  HT4,  HT1A  or  dopamine  D1  receptor  systems  [50],  employed 
enhancement of respiratory rhythm at receptor sites in the pre-Bötzinger complex that 
are  not  expressed  in  the  spinal  cord  or  other  neuronal  structures  relevant  for 
mediating opioid-induced analgesia. The present study shows that there is a possibility 
to  counter  opioid effects  on  respiration  without  impeding  analgesic  opioid effects. 
Though receptor sites are also expressed outside the pre-Bötzinger complex in the 
central nervous system ampakines are a promising alternative, as they were not found 
to counteract opioid-induced analgesia [4] for reasons not yet completely understood. 
Additional approaches to selectively counteract opioid-induced ventilatory depression 
include the use of the microglial inhibitor minocycline [51], which has not yet been 
tried in humans, and the unspecific respiratory stimulant doxapram [52] not clinically 
used due to its side effect profile (hypertension, tachycardia, tremor, sweating, panic 
attacks,  convulsions).  The  multitude  of  attempts  to  find  a  selective  antidote 
counteracting opioid induced ventilatory depression underlines the clinical relevance 
of such an antidote. 
Data  from  animal  studies  suggests  that  opioids  exert  their  ventilatory  depressive 
effects in part by their direct action at µ-opioid receptors expressed on neurons of the 
pre-Bötzinger complex, which is a small area in the ventrolateral medulla that is critical 
for the generation of inspiratory rhythm, in addition to other respiratory nuclei that 
modulate  pre-Bötzinger  function  [53].  The  neurotransmitter  glutamate,  acting  via Discussion 
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AMPA  receptors,  is  a  critical  component  for  the  generation  of  respiratory  rhythm 
within  the  pre-Bötzinger  complex  [31,  54-55].  Thus,  mechanistically,  a  signiﬁcant 
component of the CX717 effect can be explained by accentuation of AMPA receptor-
mediated glutamatergic excitation that will counteract the opioid receptor-mediated 
suppression of pre-Bötzinger neuronal excitability [4]. 
Reversing effects of CX717 on alfentanil induced ventilatory depression were captured 
by all measured ventilatory parameters (Figure 7, Figure 8 and Table 2). The combined 
measurement of respiratory rate and CO2 responsiveness to study opioid effects on 
ventilation is a well established approach [56-59] to provide clinically meaningful data 
[60]. With respect to ventilatory depression, it is thought that opioids with slower 
receptor binding, e.g., morphine, may be safer than those that bind more quickly, i.e., 
alfentanil and remifentanil, despite equianalgesic effects [61]. It is suggested that with 
a gradual increase in opioid levels, i.e., due to administration of a slowly equilibrating 
opioid  such  as  morphine,  progressive  respiratory  depression  causes  gradual 
hypercapnia  that  contributes  to  the  maintenance  of  respiration  [61].  In  contrast, 
ventilatory  depression  induced  by  a  rapidly  equilibrating opioid,  such as  alfentanil, 
follows a typical time related sequence until complete apnea is observed [62]. It starts 
with a (i) reduction in respiratory rate with partial compensation of tidal volume. This 
is followed by (ii) a respiration that is only "kicked off" by external stimuli such as noise 
or  pain.  Subsequently  (iii),  the  patient  "forgets"  respiration  but  can  be  asked  to 
breathe [63]. Finally (iv), complete apnea occurs where in spite of external stimuli or 
commands the patient cannot take a deep breath.  
Ampakine co-administration with opioid analgesics may be particularly beneficial in a 
setting  requiring  rapid  opioid  titration  such  as  the  post-surgical  recovery  room  or 
ward. These settings pose an imminent risk of severe and sometimes fatal opioid-
induced  ventilatory  depression  [17].  Preventive  administration  of  CX717  opens  a 
possibility to significantly increase the therapeutic window of opioids and reduce the 
risk of severe respiratory depression. However, the present oral formulation of CX717 
is  not  yet  ideally  suited  for  the  post-surgical  setting  because  maximum  plasma 
concentrations peak at 2 h after administration and oral administration is often not Discussion 
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possible in the peri-operative setting. Therefore, the development of an intravenous 
formulation will be necessary to meet this clinical demand.  
The  examined  dose  of  CX717,  by  some  measures,  did  not  completely  reverse 
respiratory depression induced by one particular target concentration of alfentanil. 
Therefore, various and higher doses of the ampakine should be studied against various 
opioid doses. The positive outcome of this proof-of-concept is encouraging for further 
developing CX717 for its clinical use. In this sense it is noteworthy that a higher dose of 
CX717 (2100 mg) has been found tolerable (unpublished data).  
Higher  doses  of  the  ampakine  raise  the  question  of  interference  with  analgesia 
because  analgesic  effects  of  alfentanil  were  slightly  reduced  during  the  CX717 
condition as compared to the placebo condition. This effect was non-significant and 
therefore observed at a lower statistical power of 0.45 for the effects of CX717 on the 
alfentanil effects on electrical pain, and of only 0.1 for heat pain. A non-significant 
effect indicates that the power was too low to observe it at p < 0.05, and increasing 
the  power  would  require  more  observations.  In  the  present  case,  to  obtain  the 
necessary power of 0.8 to observe the decrease in alfentanil analgesia at p < 0.05, a 
minimum of 129 subjects would be needed. This is a post-hoc case-number calculation 
based on the observed difference (CX717 versus placebo) in the percent changes from 
baseline of 18.7 ± 75.4% for electrical pain tolerance. With heat pain, 258 cases would 
be  needed  to  find  the  difference  between  placebo  and  CX717  conditions  of  1.8  ± 
10.3% in the increase in pain tolerance statistically significant.  
However, results from animal research [4] encourage the expectation that the effect 
size  for  reduction  of  analgesia  stays  favourably  smaller  than  that  for  reduction  of 
ventilatory  depression.  That  is,  the  effect  of  CX717  on  opioid  induced  ventilatory 
depression  could  be  gradually  increased  with  doses  between  5  –  33  mg/kg. 
Importantly, 15 mg/kg CX717 rescued Sprague-Dawley rats from a lethal dose of 80 
µg/kg  fentanyl.  Significantly,  CX717  countered  fentanyl-induced  depression  of 
respiratory frequency without suppressing analgesia [4]. This supports the expectation 
that the selectivity of the antagonism for respiratory but not analgesic opioid effects 
will persist when higher opioid and CX717 dosages will be administered.  Discussion 
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Although  heat-pain  tolerance  values  did  not  return  to  the  expected  values  of  the 
baseline measurements after administration of naloxone, this is explainable by the so 
called re-kindling effect [64] and should not be attributed to an incompetence of the 
method to capture opioid antagonistic effects. The stimulated area remains sensitized 
by provoking the same area with heat during repetitive measurements, re-kindling 
even  with  a  previous  non-painful  stimulus  is  in  this  situation  sufficient  to  activate 
sensitized  nociceptors. Nevertheless,  the effect  is  reflected in both the verum and 
placebo  condition  in  our  study  and  could  thus  not  be  attributed  to  the  study 
medication. Re-kindling in the context of the here used model to quantify heat pain 
tolerance in combination with capsaicin pre-application is examined at the present in a 
continuative  study,  where  the  effects  of  different  time  intervals  and  number  of 
repetitions on heat pain tolerance assessment are being investigated.  
In  conclusion,  we  successfully  demonstrated  the  principle  of  ampakine  mediated 
potentiation  of  AMPA-type  glutamate  receptors  for  prevention  of  opioid  induced 
respiratory effects from animal research into humans. However, the principle is not yet 
fully  clinically  applicable.  There  is  a  need  for  additional  testing  of  higher  doses  of 
CX717 and opioids. On the other hand, there is need for an intravenous formulation 
for administration in humans in pertinent clinical settings. Nevertheless, the ampakine 
CX717 seems to be the first selective antidote to counteract opioid-induced ventilatory 
depression without decreasing analgesia in humans.  Abstract 
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5  Abstract 
Despite  sensible  guidelines  for  the use  of  opioid  analgesics,  respiratory  depression 
remains a significant risk with a possibility of fatal outcomes. Clinicians need to find a 
balance of analgesia with manageable respiratory effects. The ampakine CX717 (Cortex 
Pharmaceuticals,  Irvine,  CA,  USA),  an  allosteric  enhancer  of  glutamate-stimulated 
AMPA receptor activation, has been shown to counteract opioid-induced respiratory 
depression in rats while preserving opioid-induced analgesia. 
Adopting a translational approach, we orally administered 1500 mg of CX717 to 16 
male healthy volunteers in a placebo controlled double-blind study. Starting 100 min 
after  CX717  or  placebo  intake,  alfentanil  was  administered  by  computerized 
intravenous infusion targeting a plateau of effective alfentanil plasma concentrations 
of 100 ng/ml. One hour after start of opioid infusion, its effects were antagonized by 
intravenous injection of 1.6 mg of the classical opioid antidote naloxone.  
Respiration was quantified prior to drug administration (baseline), during alfentanil 
infusion and after naloxone administration by (i) counting the spontaneous respiratory 
frequency at rest and (ii) by employing hypercapnic challenge with CO2 rebreathing 
that  assessed  the  expiratory  volume  at  a  carbon  dioxide  concentration  in  the 
breathable air of 55% (VE55). Pain was quantified at the same time points, immediately 
after assessment of respiratory parameters, by (i) measuring the tolerance to electrical 
stimuli (5 Hz sine increased by 0.2 mA/s from 0 to 20 mA and applied via two gold 
electrodes placed on the medial and lateral side of the mid-phalanx of the right middle 
finger) and (ii) by measuring the tolerance to heat (increased by 0.3°C/s from 32 to 
52.5°C applied to a 3 x 3 cm
2 skin area of the left volar forearm, after sensitization with 
0.15 g capsaicin cream 0.1%). 
CX717 was tolerated by all subjects without side effects that  would have required 
medical  intervention.  We  observed  that  CX717  was  approximately  as  effective  as 
naloxone  in  reversing  the  opioid  induced  reduction  of  the  respiratory  frequency. 
Despite  the  presence  of  high  plasma  alfentanil  concentrations,  the  respiratory 
frequency decreased only by 8.9 ± 22.4% when CX717 was pre-administered, which Abstract 
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was  comparable  to  the  7.0  ±  19.3%  decrease  observed  after  administration  of 
naloxone. In contrast, after placebo pre-administration the respiratory rate decreased 
by 30.0 ± 21.3% (p=0.0054 for CX717 versus placebo). In agreement with this, periods 
of a very low respiratory frequency of ≤ 4 min
-1 under alfentanil alone were shortened 
by ampakine pre-dosing by 52.9% (p=0.0182 for CX717 versus placebo). Furthermore, 
VE55  was  decreased  during  alfentanil  infusion  by  55.9  ±  16.7%  under  placebo  pre-
administration but only by 46.0 ± 18.1% under CX717 pre-administration (p=0.017 for 
CX717 versus placebo).  
Most importantly, in contrast to naloxone, CX717 had no effect on opioid induced 
analgesia. Alfentanil increased the pain tolerance to electrical stimuli by 68.7 ± 59.5% 
with placebo pre-administration. With CX717 pre-administration, the increase of the 
electrical pain tolerance was similar (54.6 ± 56.7%, p=0.1 for CX717 versus placebo). 
Similarly, alfentanil increased the heat pain tolerance threshold by 24.6 ± 10.0% with 
placebo  pre-administration.  Ampakine  co-administration  had  also  no  effect  on  the 
increase of the heat pain tolerance of the capsaicin-sensitized skin (23.1 ± 8.3%, p=0.46 
for CX717 versus placebo).  
The  results  of  this  study  allow  us  to  draw  the  conclusion,  that  opioid  induced 
ventilatory depression can be selectively antagonized in humans by co-administering 
an ampakine. This is the first successful translation of a selective antagonism of opioid-
induced respiratory depression from animal research into application in humans.  
Ampakines,  namely  CX717,  thus  are  the  first  selective  antidote  for  opioid-induced 
respiratory depression without loss of analgesia, available for the use in humans.  Deutsche Zusammenfassung 
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6  Deutsche Zusammenfassung 
Die  Atemdepression  ist  die  gefährlichste  Nebenwirkung  von  Opioidanalgetika.  Ihre 
selektive Antagonisierung, ohne die analgetischen Wirkungen zu beeinflussen, wäre 
ein  bedeutender  therapeutischer  Fortschritt.  Molekularbiologische  und 
tierexperimentelle Befunden zeigten, dass möglicherweise das Ampakin CX717 (Cortex 
Pharmaceuticals,  Irvine,  CA,  USA)  dafür  geeignet  ist.  Es  verstärkte  über  eine 
allosterische Bindungsstelle die Wirkung von Glutamat am AMPA-Rezeptor und konnte 
in  einem  Tiermodell  an  Ratten  die  opioid-induzierte  Atemdepression  bei 
gleichbleibender Analgesie verhindern. 
In  einem  translationalen  Ansatz  führten  wir  eine  doppelblind  angelegte, 
placebokontrollierte  Studie  in  16  gesunden  männlichen  Probanden  durch,  denen 
1500 mg  CX717  oral  verabreicht  wurden,  und  100  min  später  computergesteuert 
Alfentanil über 2 h infundiert wurde (Alfentanil-Plasmazielkonzentration im „steady-
state“  von  100  ng/ml).  Eine  Stunde  nach  Start  der  Opioid-Infusion  wurden  die 
Wirkungen  des  Alfentanils  durch  die  intravenöse  Gabe  von  1.6  mg  Naloxon 
antagonisiert. Die Wirkungen des Opioids auf Atmung und Schmerz wurden jeweils 
mittels  zweier  experimenteller  Parameter  quantifiziert.  Die  Atemdepression  wurde 
mittels  Aufzeichnung  der  spontanen  Atemfrequenz  in  Ruhe  sowie  mittels  CO2-
Rückatemversuch gemessen, bei welcher das exspiratorische Volumen bei einer CO2-
Konzentration von 55% in der Einatemluft (VE55) als Hauptzielparameter diente. Die 
Schmerzwahrnehmung  wurde  als  Schmerztoleranz  auf  elektrische  Stimuli 
(sinusförmige  Reize  einer  Stromstärke  von  0-20  mA;  Applikation  über  zwei 
Goldelektroden am mittleren Fingerendgelenks des rechten Mittelfingers) sowie als 
Toleranz  auf  Hitze-induzierten  Schmerz  gemessen  (Temperaturanstieg:  0.3°C/s  von 
32.5 -52.5, Applikation über eine 3 x 3 cm² große Hautfläche an der volaren Seite des 
linken Unterarms, nach Sensibilisierung der Haut mit 0.15 g Capsaicin Creme 0.1%). 
Während der Alfentanil-Infusion (Plasmakonzentrationen ca. XXX) verminderte sich die 
Atemfrequenz unter Gabe von CX717 nur um 8.9 ± 22.4%, vergleichbar mit 7.0 ± 19.3% 
Rückgang nach Gabe von Naloxon. Dagegen kam es unter Placebo zu einer Senkung Deutsche Zusammenfassung 
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der  Atemfrequenz  um 30  ±  21.3%  (p=0.0054 für  CX717  versus  Placebo).  Zusätzlich 
wurden Perioden mit sehr niedriger Atemfrequenz von ≤ 4 min
-1 unter Alfentanil nach 
pre-Medikation mit CX717 um 52.9% verkürzt (p=0.0182 für CX717 versus Placebo). 
Darüber hinaus war die VE55 während der Alfentanil Infusion nach Placebo-Gabe um 
55.9 ± 16.7% verringert, während es nach Gabe von CX717 nur zu einer Verminderung 
von  46.0  ±  18.1%  kam  (p=0.017  für  CX717  versus  Placebo).  Im  Gegensatz  zu  der 
signifikanten  Antagonisierung  der  atemdepressiven  Wirkungen  von  Alfentanil  hatte 
CX717  keine  statistisch  signifikanten  Auswirkungen  auf  die  alfentanilinduzierte 
Analgesie, während Naloxon unselektiv auch die Analgesie antagonisierte. Alfentanil 
allein  erhöhte die  Schmerztoleranz  auf elektrische  Stimuli  um  68.7  ±  59.5%.  Unter 
Gabe von CX717 war die Steigerung der elektrischen Schmerztoleranz ähnlich (54.6 ± 
56.7%, p=0.1 für CX717 versus Placebo). Entsprechend erhöhte die alleinige Gabe von 
Alfentanil die Hitze-Toleranz-Schwelle um 24.6 ± 10.0%, während eine pre-Medikation 
mit CX717 auch hier keinen Einfluss auf den Anstieg der Hitzetoleranz hatte (23.1 ± 
8.3%, p=0.46 für CX717 versus Placebo). 
Aus diesen Ergebnissen kann man einen selektiven Antagonismus der atemdepressiven 
Wirkungen des Opioids Alfentanil durch das Ampakin CX717 ableiten. Die vorliegende 
Arbeit  stellt  also  eine  erfolgreiche  Translation  tierexperimenteller 
Forschungsergebnisse  in  den  Menschen  dar.  CX717  stellt  somit  das  erste  selektive 
Antidot für die Opioid-induzierte Atemdepression beim Menschen dar, das nicht zu 
einem Verlust der Analgesie führt.  
 Literature 
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8  Appendix 
8.1  Abbreviations 
e.g.    Example given 
F    F-value 
i.e.    Id est  
kg    Kilogram 
kPa    Kilopascal 
l    Liter 
LC-MS/MS  Liquid chromatographic tandem mass spectrometric 
m    Meter 
mA    Milliampere 
mg    Milligram 
ml    Milliliter 
min    Minute 
mM    Millimolar 
mmHG   Millimeters of Mercury 
pCO2    CO2 partial pressure 
s    Second 
t½(ke0)    Equilibration time 
µg    Microgram 
VAS    Visual analog scale 
VE    Expiratory volume Appendix 
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